Q32 Bio Inc. (QTTB): Total Assets
$61.78M
As of 2025-12-31
$115.87M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.78M | -33.1% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $92.33M | +96.2% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $47.06M | n/c | 2025-03-11, Balance as of period end |
| 2022-12-31 | $228.47M | +7.9% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $211.72M | -19.7% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $263.74M | -15.1% | 2022-03-23, Balance as of period end |
| 2019-12-31 | $310.57M | +19.9% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $259.09M | +88.4% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $137.53M | n/a | 2019-03-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $61.78M | -33.1% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $1.30B | -22.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $280.41M | -7.7% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $808.06M | +76.5% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $105.01M | -15.4% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Journey Medical Corp (DERM) | 2025-12-31 | $94.59M | +17.9% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $398.69M | +26.0% |
Compare QTTB, AGIO, NKTR, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗